David Reed Powell

This inventor holds 6 USPTO granted patents and 5 published patent applications, plus 4 CIPO patents and 4 EPO patents. Top assignee: Lexicon Pharmaceuticals, Inc.. Active years: 2010-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David Reed Powell. Retrieved from https://idiyas.com/inventor/david-reed-powell

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 (Patent Applications = 5)

% Patents Active = 83.3

CIPO Patents = 4

EPO Patents = 4 (Patent Applications = 2)

Average Co-Inventor Count = 6.6

ph-index = 4

Forward Citations = 79(Granted Patents)

Company Filing History:

6 out of 89

Lexicon Pharmaceuticals, Inc.

patents

Years Active: 2010-2021

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11059907 - Antibodies that bind Notum Pectinacetylesterase (2021-07-13),

2. 8742075 - Monoclonal antibodies against ANGPTL3 (2014-06-03),

3. 8591891 - Monoclonal antibodies against ANGPTL4 (2013-11-26),

4. 8092796 - Monoclonal antibodies against ANGPTL4 (2012-01-10),

5. 7935796 - Monoclonal antibodies against ANGPTL3 (2011-05-03),

6. 7655762 - Monoclonal antibodies against ANGPTL4 (2010-02-02),

Title: David Reed Powell: Innovator in Antibody Development

Introduction

David Reed Powell is a prominent inventor based in Houston, TX (US). He has made significant contributions to the field of biotechnology, particularly in the development of antibodies for therapeutic applications. With a total of 6 patents to his name, Powell's work has the potential to impact the treatment of various diseases and disorders.

Latest Patents

Among his latest patents, Powell has developed antibodies that bind to Notum Pectinacetylesterase. These antibodies are designed to neutralize the enzyme, and the compositions comprising them can be used to treat diseases and disorders affecting the bone. Additionally, he has created monoclonal antibodies against ANGPTL3, which specifically bind to this protein. These antibodies can neutralize at least one activity of ANGPTL3 and are intended for use in treating disorders of lipid metabolism.

Career Highlights

David Reed Powell is currently associated with Lexicon Pharmaceuticals, Inc., where he continues to advance his research and development efforts. His innovative work in antibody technology has positioned him as a key figure in the biotechnology sector.

Collaborations

Powell has collaborated with notable colleagues, including Gregory M Landes and Seokjoo Hong, to further enhance the impact of his research and inventions.

Conclusion

David Reed Powell's contributions to antibody development exemplify the innovative spirit of modern biotechnology. His patents and ongoing research hold promise for advancing medical treatments and improving patient outcomes.

Profile summary based on public USPTO records.